Adjustments to Current Assets
Adjustments to Total Assets
Adjustments to Current Liabilities
Adjustments to Total Liabilities
Adjustments to Stockholders’ Equity
Adjustments to Capitalization Table
Adjustments to Revenues
Adjustments to Reported Income

Celgene Corp., adjusted current assets

US$ in millions

	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
As Reported
Current assets	9,067)	14,892)	10,868)	9,401)	9,713)
Adjustments
Add: Allowance for doubtful accounts	16)	16)	15)	18)	21)
Less: Current deferred tax assets¹	—)	—)	—)	—)	12)
After Adjustment
Adjusted current assets	9,083)	14,908)	10,883)	9,419)	9,722)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Current deferred tax assets. See details »

Download chart

Celgene Corp., adjusted total assets

US$ in millions

	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
As Reported
Total assets	35,480)	30,141)	28,086)	27,053)	17,340)
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	375)	209)	191)	206)	197)
Add: Allowance for doubtful accounts	16)	16)	15)	18)	21)
Less: Current deferred tax assets²	—)	—)	—)	—)	12)
Less: Non-current deferred tax assets (included in Other non-current assets)³	24)	23)	138)	66)	57)
After Adjustment
Adjusted total assets	35,847)	30,343)	28,154)	27,212)	17,489)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

² Current deferred tax assets. See details »

³ Non-current deferred tax assets (included in Other non-current assets). See details »

Download chart

Celgene Corp., adjusted current liabilities

US$ in millions

	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
As Reported
Current liabilities	4,057)	2,987)	2,959)	1,969)	2,112)
Adjustments
Less: Current deferred tax liabilities¹	—)	—)	—)	—)	131)
Less: Current portion of deferred revenue	73)	75)	55)	61)	29)
After Adjustment
Adjusted current liabilities	3,984)	2,912)	2,904)	1,908)	1,953)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Current deferred tax liabilities. See details »

Download chart

Celgene Corp., adjusted total liabilities

US$ in millions

	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
As Reported
Total liabilities	29,319)	23,220)	21,486)	21,134)	10,815)
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)¹	375)	209)	191)	206)	197)
Less: Current deferred tax liabilities²	—)	—)	—)	—)	131)
Less: Non-current deferred tax liabilities³	2,753)	1,327)	—)	378)	556)
Less: Deferred revenue	146)	109)	83)	91)	56)
After Adjustment
Adjusted total liabilities	26,795)	21,993)	21,594)	20,872)	10,269)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Current deferred tax liabilities. See details »

³ Non-current deferred tax liabilities. See details »

Download chart

Celgene Corp., adjusted stockholders’ equity

US$ in millions

	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
As Reported
Stockholders’ equity	6,161)	6,921)	6,599)	5,919)	6,525)
Adjustments
Less: Net deferred tax asset (liability)¹	(2,729)	(1,304)	138)	(312)	(619)
Add: Allowance for doubtful accounts	16)	16)	15)	18)	21)
Add: Deferred revenue	146)	109)	83)	91)	56)
After Adjustment
Adjusted stockholders’ equity	9,052)	8,350)	6,560)	6,340)	7,220)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Net deferred tax asset (liability). See details »

Download chart

Celgene Corp., adjusted capitalization table

US$ in millions

	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
As Reported
Short-term borrowings and current portion of long-term debt	501)	—)	501)	—)	606)
Long-term debt, net of discount, excluding current portion	19,769)	15,838)	13,789)	14,250)	6,266)
Total reported debt	20,270)	15,838)	14,289)	14,250)	6,872)
Stockholders’ equity	6,161)	6,921)	6,599)	5,919)	6,525)
Total reported capital	26,431)	22,759)	20,889)	20,169)	13,396)
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)¹	375)	209)	191)	206)	197)
Adjusted total debt	20,645)	16,047)	14,480)	14,456)	7,068)
Adjustments to Equity
Less: Net deferred tax asset (liability)²	(2,729)	(1,304)	138)	(312)	(619)
Add: Allowance for doubtful accounts	16)	16)	15)	18)	21)
Add: Deferred revenue	146)	109)	83)	91)	56)
Adjusted stockholders’ equity	9,052)	8,350)	6,560)	6,340)	7,220)
After Adjustment
Adjusted total capital	29,697)	24,397)	21,040)	20,796)	14,289)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Net deferred tax asset (liability). See details »

Download chart

Celgene Corp., adjusted net product sales

US$ in millions

12 months ended:	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
As Reported
Net product sales	15,265)	12,973)	11,185)	9,161)	7,564)
Adjustment
Add: Increase (decrease) in deferred revenue	37)	26)	(8)	34)	5)
After Adjustment
Adjusted net product sales	15,302)	12,999)	11,177)	9,195)	7,569)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

Download chart

Celgene Corp., adjusted net income

US$ in millions

12 months ended:	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
As Reported
Net income	4,046)	2,940)	1,999)	1,602)	2,000)
Adjustments
Add: Deferred income tax expense (benefit)¹	32)	(1,330)	(344)	(33)	(272)
Add: Increase (decrease) in allowance for doubtful accounts	—)	1)	(3)	(3)	(7)
Add: Increase (decrease) in deferred revenue	37)	26)	(8)	34)	5)
Add: Other comprehensive income (loss)	233)	(102)	(349)	(147)	821)
After Adjustment
Adjusted net income	4,348)	1,535)	1,296)	1,453)	2,546)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Deferred income tax expense (benefit). See details »

Download chart

Celgene Corp. (NASDAQ:CELG)

Adjustments to Financial Statements

Adjustments to Current Assets

Adjustments to Total Assets

Adjustments to Current Liabilities

Adjustments to Total Liabilities

Adjustments to Stockholders’ Equity

Adjustments to Capitalization Table

Adjustments to Revenues

Adjustments to Reported Income